about
Thyroid microcarcinoma approach: a ten year experience.The Ribonucleic Complex HuR-MALAT1 Represses CD133 Expression and Suppresses Epithelial-Mesenchymal Transition in Breast Cancer.Erythropoietin: recent developments in the treatment of spinal cord injuryRisk factors for accelerated atherosclerosis in patients with systemic lupus erythematosus.Xanthine oxido-reductase activity in ischemic human and rat intestine.Glutathionyl-hemoglobin levels in carotid endarterectomy: a pilot study on 12 cases clinically uneventful.Necessity of therapy for post-thyroidectomy hypocalcaemia: a multi-centre experience.Enhanced brain release of erythropoietin, cytokines and NO during carotid clamping.Common carotid artery pseudoaneurysm after neck dissection: colour Doppler ultrasound and multidetector computed tomography findings.Multidisciplinary approach to follicular thyroid carcinoma with giant mandibular and multiple sites metastases Case report.Loss of heterozygosity of the NOS3 dinucleotide repeat marker in atherosclerotic plaques of human carotid arteries[Prevalence of carotid kinking in a resident population. Partial results of the OPI (Objective Prevention of Ictus)]Genetic control of chemokines in severe human internal carotid artery stenosisBreast cancer progression and host polymorphisms in the chemokine system: role of the macrophage chemoattractant protein-1 (MCP-1) -2518 G alleleGenetic contribution to carotid vascular disease in patients with systemic lupus erythematosusAdipose-Derived Stem Cells from Fat Tissue of Breast Cancer Microenvironment Present Altered Adipogenic Differentiation Capabilities
P50
Q38154065-AA1242CA-797F-4040-9234-EEEFDFD30ED6Q38769820-39ABCF99-96B1-49C1-84F4-6F2B97014504Q42797884-FBAF7496-81E3-4CBF-AED2-E5C6448B8856Q43049585-1584AAA8-E3D9-404D-93F9-6789348B7CBBQ45204065-AF16A3F5-2F4E-49FC-928E-56726C34BEE0Q48016363-D6B808E6-5E41-446B-9B8B-A8A0D1FDCEB4Q51047557-09F7E6CF-D847-4994-833A-09E808EEC573Q52147638-28C03FB5-FC18-4D69-AFF8-B05E99CD1464Q53510192-A9BE418C-D7FB-4B80-96A0-185484A8FDA2Q53605053-9CE5C650-3563-4A11-B049-86F8058E508DQ59504124-0976AF64-33E1-4CED-878A-4C1BBA0591E4Q72833741-61316368-CB71-4694-A9B8-9A6BBF41BEB9Q80149834-31230635-DEDC-4AC3-BF19-EC3741D61DFAQ81341216-B4162F3E-65CA-4250-B50E-6C69AC8BC519Q81536457-F1603905-5BFF-48F6-87A8-6786FA4F31A5Q90069833-AA4C99B2-E25E-498C-8638-5AB6C828AF1E
P50
description
researcher
@en
wetenschapper
@nl
name
Ghilardi G
@nl
Giorgio Ghilardi
@en
type
label
Ghilardi G
@nl
Giorgio Ghilardi
@en
altLabel
Ghilardi G
@en
prefLabel
Ghilardi G
@nl
Giorgio Ghilardi
@en
P106
P31
P496
0000-0002-0269-5761